Medicine & Life Sciences
Neoplasms
100%
Pharmacokinetics
43%
Clinical Trials
36%
LY-2157299
35%
Safety
33%
Phosphatidylinositol 3-Kinases
31%
Glioblastoma
31%
pembrolizumab
28%
Biomarkers
28%
Maximum Tolerated Dose
28%
Therapeutics
28%
Alpelisib
27%
NVP-BKM120
26%
Phosphatidylinositol 3-Kinase
24%
Breast Neoplasms
24%
Immunotherapy
23%
Drug Development
23%
Precision Medicine
22%
Mutation
20%
Fibroblast Growth Factor Receptors
18%
Glioma
18%
Mechanistic Target of Rapamycin Complex 1
17%
Survival
16%
Pharmaceutical Preparations
15%
XL147
15%
Phosphotransferases
15%
Phosphoinositide-3 Kinase Inhibitors
13%
selinexor
13%
Response Evaluation Criteria in Solid Tumors
12%
Paclitaxel
12%
Bevacizumab
11%
Lomustine
11%
GDC-0084
11%
Transforming Growth Factors
10%
Progression-Free Survival
10%
Middle East Respiratory Syndrome Coronavirus
10%
New World Camelids
10%
High-Throughput Nucleotide Sequencing
10%
Clinical Trials, Phase I
10%
HM781-36B
10%
Appointments and Schedules
9%
Somatomedin Receptors
9%
Triple Negative Breast Neoplasms
9%
Colorectal Neoplasms
9%
Non-Small Cell Lung Carcinoma
9%
Genes
8%
Multicenter Studies
8%
MEK162
8%
Nausea
8%
Patient Selection
8%